Sanjivani Paranteral Q4 FY26 Results: PAT of Rs 0.5485 (Rs 54.85 lakhs) crore Intravenous Fluids and Pharma

Sanjivani Paranteral Q4 results were announced on May 14, 2026, at the company’s board meeting. the company PAT fell sharply to Rs 54.85 lakhs (Rs 0.5485 crore) from Rs 2.7763 crore in Q3 FY26. Revenue declined to Rs 13.8091 crore from Rs 22.3580 crore QoQ. FY26 annual EPS Rs 5.49 vs Rs 6.66 in FY25. The company manufactures intravenous fluids and pharmaceutical products. Investors tracking the company will find complete financial data, analysis, and FY27 outlook in this article.

Click Here – Get Free Investment Predictions

Sanjivani Paranteral Q4 FY26 Key Financial Highlights

Metric	Q4 FY26	Comparison
PAT (Net Profit)	Rs 0.5485 (Rs 54.85 lakhs) crore	Q4 FY25 / Reference | vs Rs 2.7763 (Q3 FY26) crore
Revenue from Operations	Rs 13.8091 crore	Q4 FY26 Revenue | vs Rs 22.3580 (Q3 FY26) crore
Ticker	SANJIVANI	Sector: Intravenous Fluids and Pharma

Screen the best stocks on the Univest Screener.

Sanjivani Paranteral Performance Analysis

The company results reflect the company’s operational performance during the January to March 2026 quarter. the company PAT fell sharply to Rs 54.85 lakhs (Rs 0.5485 crore) from Rs 2.7763 crore in Q3 FY26. Revenue declined to Rs 13.8091 crore from Rs 22.3580 crore QoQ. FY26 ann Investors and analysts monitoring the company results will focus on FY27 revenue guidance, margin trajectory, and management commentary on business outlook.

The company performance positions the company for FY27. Track the company analyst ratings and live stock price on the Univest Screener for real-time investment insights.

Sanjivani Paranteral FY27 Outlook

Post Sanjivani, investor focus for FY27 will be on revenue growth momentum, margin expansion, new order wins, and sector-specific tailwinds in the Intravenous Fluids and Pharma space. The Sanjivani results highlight areas for improvement in the company’s execution capabilities. Track Sanjivani updates on the Univest Screener for analyst views and FY27 earnings estimates.

Download the Univest iOS App or the Univest Android App to track live price and Q4 FY26 earnings updates.

Frequently Asked Questions on Sanjivani Paranteral Q4 FY26 Results

What is Sanjivani Paranteral Q4 FY26 PAT?

Ans. Sanjivani Paranteral Q4 FY26 profit after tax was Rs 0.5485 (Rs 54.85 lakhs) crore.

When did Sanjivani Paranteral announce Q4 FY26 results?

Ans. the company results were announced on May 14, 2026, at the company’s board meeting and filed with BSE and NSE.

What is the FY27 outlook for Sanjivani Paranteral?

Ans. Post the company results, investors will track FY27 guidance and growth strategies in the Intravenous Fluids and Pharma sector. Track live updates on the Univest Screener.

Where can I track Sanjivani Paranteral Q4 FY26 live data?

Ans. Track the company live stock price, analyst ratings, and earnings updates on the Univest Screener for real-time investment data.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.